Daniel Cagney
A5043519166- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Management of metastatic bone disease
- Advanced Radiotherapy Techniques
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Pancreatic and Hepatic Oncology Research
- Prostate Cancer Diagnosis and Treatment
- Meningioma and schwannoma management
- Head and Neck Cancer Studies
- Spine and Intervertebral Disc Pathology
- Advances in Oncology and Radiotherapy
- Palliative Care and End-of-Life Issues
- COVID-19 and healthcare impacts
- Melanoma and MAPK Pathways
- Economic and Financial Impacts of Cancer
- Frailty in Older Adults
- Inflammatory Biomarkers in Disease Prognosis
Harvard University
2016-2023
Dana-Farber Brigham Cancer Center
2016-2023
Brigham and Women's Hospital
2016-2023
Dana-Farber Cancer Institute
2016-2023
Mater Misericordiae University Hospital
2021-2023
Cambridge Health Alliance
2021
Cambridge Hospital
2021
Center for Neuro-Oncology
2021
Radiation Oncology Associates
2021
Foundation Medicine (United States)
2021
Brain metastases are associated with significant morbidity and mortality. Population-level data describing the incidence prognosis of patients brain lacking. The aim this study was to characterize at diagnosis systemic malignancy using recently released from Surveillance, Epidemiology, End Results (SEER) program.
Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published diagnosis-specific Graded Prognostic Assessment (GPA). Updates larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes this work are to present all updated indices in a single report guide treatment choice, stratify...
This study investigates the association between immunotherapy and symptomatic radiation necrosis in patients with melanoma, non–small-cell lung cancer, or renal cell carcinoma newly diagnosed brain metastases treated stereotactic therapy.
Population-based estimates of the incidence and prognosis brain metastases at diagnosis breast cancer are lacking.To characterize proportions median survivals patients with time diagnosis.Patients were identified using Surveillance, Epidemiology, End Results (SEER) database National Cancer Institute. Data stratified by subtype, age, sex, race. Multivariable logistic Cox regression performed to identify predictors presence factors associated all-cause mortality, respectively. For incidence,...
<h3>Importance</h3> Although stereotactic radiosurgery (SRS) is preferred for limited brain metastases from most histologies, whole-brain radiotherapy (WBRT) has remained the standard of care patients with small cell lung cancer. Data on SRS are limited. <h3>Objective</h3> To characterize and compare first-line outcomes (without prior WBRT or prophylactic cranial irradiation) those WBRT. <h3>Design, Setting, Participants</h3> FIRE-SCLC (First-line Radiosurgery Small-Cell Lung Cancer) was a...
Brain metastasis impacts greatly on patients' quality of life and survival. The phase I NANO-RAD trial assessed the safety maximum tolerated dose systemic administration a novel gadolinium-based nanoparticle, AGuIX, in combination with whole brain radiotherapy patients multiple metastases not suitable for stereotactic radiotherapy.Patients measurable received escalating doses AGuIX nanoparticles (15, 30, 50, 75, or 100 mg/kg intravenously) day initiation WBRT (30 Gy 10 fractions) 5 cohorts 3...
PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria are widely used high-grade glioma clinical trials. We compared the RANO with updated modifications (modified [mRANO] and immunotherapy [iRANO] criteria) patients newly diagnosed glioblastoma (nGBM) recurrent GBM (rGBM) to evaluate performance of each set inform development planned 2.0 update. MATERIALS AND METHODS Evaluation tumor measurements fluid-attenuated inversion recovery (FLAIR) sequences were performed by blinded...
The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human 2 CC-115 deoxyribonucleic acid-dependent protein kinase/mammalian target rapamycin inhibitor]) were...
Neurosurgical resection represents an important management strategy for patients with large, symptomatic brain metastases and increasingly is followed by stereotactic radiation as opposed to whole-brain radiation. Whether neurosurgical associated tumor spread beyond the site adjuvant field remains unknown.To characterize association incidence of pachymeningeal seeding in treated radiation.Retrospective cohort study a consecutive sample newly diagnosed managed (n = 318) vs alone 870) between...
Breast cancer treatment is based on estrogen receptors (ERs), progesterone (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, status can be discordant from that at initial diagnosis. The purpose this study was to determine incidence discordance its effect survival subsequent in patients with breast brain metastases (BCBM).A retrospective database 316 who underwent craniotomy for BCBM between 2006 2017 created. Discordance considered present if ER, PR, or...
Stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) for prostate cancer allows MR-based contouring, real-time MR motion management, and daily plan adaptation. The clinical dosimetric benefits associated with SMART remain largely unknown.
Abstract Introduction Historical reservations regarding stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases include concerns short-interval and diffuse central nervous system (CNS) progression, poor prognoses, increased neurological mortality specific to SCLC histology. We compared SRS outcomes non-small cell (NSCLC) where is well established. Methods Multicenter first-line NSCLC from 2000 2022 were retrospectively collected (n = 892 SCLC, n 4785 NSCLC). Data...
Abstract Background Brain metastases (BM) cause symptoms that supportive medications can alleviate. We assessed whether racial disparities exist in medication utilization after BM diagnosis. Methods Medicare-enrolled patients linked with the Surveillance, Epidemiology, and End Results program (SEER) who had diagnoses of between 2007 2016 were identified. Fourteen classes studied: non-opioid analgesics, opioids, anti-emetics, anti-epileptics, headache-targeting medications, steroids,...